Abstrak
Gastropati obat antiinflamasi nonsteroid (OAINS) adalah lesi mukosa gaster yang berhubungan
dengan penggunaan OAINS. Gastropati OAINS dapat disebabkan oleh efek terperangkapnya
OAINS dalam sel mukosa gaster dan efek sistemik melalui penghambatan siklooksigenase (COX)
yang menyebabkan sintesis prostaglandin terhambat. Pencegahan dan penanganan gastropati
OAINS terdiri atas penghentian OAINS, pemilihan OAINS, dan penggunaan obat gastroprotektif
dengan mempertimbangkan risiko gastrointestinal dan kardiovaskuler. J Indon Med Assoc.
2012;62:444-9.
Kata kunci: gastropati, OAINS, patofisiologi, penanganan
Abstract
Gastropathy nonsteroidal anti-inflammatory drugs (NSAID) is a gastric mucosal lesions associated with NSAID used. The mechanisms of NSAID induced gastropathy due to topical damage
caused by ion trapping of NSAID in gastric mucosa and systemic effect by inhibiting cyclooxygenase
(COX) which causes inhibition of prostaglandins synthesis. Prevention and treatment of gastropathy
NSAID consist of cessation of NSAID, selection of NSAID, and the use of gastroprotective drugs
with gastrointestinal and cardiovascular risks consideration. J Indon Med Assoc. 2012;62:4449.
Keywords: gastropathy, NSAID, pathophysiology, treatment
444
446
Rekomendasi
Ulkus aktif
NSAID dihentikan Antagonis reseptor H2 , Protein pump inhibitor
NSAID dilanjutkan Protein pump inhibitor
Terapi profilaksis Misoprostol
Protein pump inhibitor
Pengambat COX-2 selektif
Infeksi H. pylori
Eradikasi jika terdapat ulkus aktif atau riwayat
ulkus peptik
OAINS tradisional
447
Rendah
Risiko Gastrointestinal a
Sedang
Risiko kardiovaskuler
rendah
Naproksen +
PPI/misoprostol
Risiko kardiovaskuler
tinggib
Naproksen + PPI/misoprostol
Naproksen +
PPI/misoprostol
Risiko gastrointestinal distratifikasikan menjadi rendah (tanpa faktor risiko), sedang (terdapat satu atau dua faktor risiko), dan tinggi
(faktor risiko multipel, atau terdapat riwayat komplikasi ulkus, atau terdapat penggunaan kortikosteroid atau antikoagulan). b Risiko
kardiovaskuler tinggi didefinisikan sebagai kebutuhan penggunaan aspirin dosis rendah sebagai pencegahan kejadian kardiovaskular.
Seluruh pasien dengan riwayat ulkus yang membutuhkan OAINS sebaiknya dilakukan tes terhadap H. pylori, jika terdapat infeksi,
terapi eradikasi harus dilakukan.
Tinggi
2.
3.
Simadibrata MK. Diagnosis of NSAID gastropathy and its complications. In: Simadibrata MK, Abdullah M, Syam AF, editors.
Procedings of the 4th international endoscopy workshop & international symposium on digestive disease. Jakarta: Pusat
Penerbitan Departemen IPD FK UI; 2008. p. 85-7.
Wenas NT. Pathophysiology and prevention of NSAID gastropathy. In: Simadibrata MK, Abdullah M, Syam AF, editors. The
4th international endoscopy workshop & international symposium on digestive disease. Jakarta: Pusat Penerbitan Departemen
IPD FK UI; 2008. p. 83-4.
Manan C. Gastropati obat antiinflamasi nonsteroid. In: Rani AA,
Manan C, Djojoningrat D, Simadibrata MK, Makmun D, Abdullah
M, et al, editors. Dispepsia sains dan aplikasi klinik. Jakarta:
Pusat Penerbitan Departemen IPD FKUI; 2005. p. 68-76.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Becker JC, Domschke W, Pohle T. Current approaches to prevent NSAID-induced gastropathy - COX selectivity and beyond.
Br J Clin Pharmacol. 2004;58:587-600.
Valle JD. Peptic ulcer disease and related disorders. In: Kasper
DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL,
et al, editors. Harrisons principle of internal medicine. 16th Ed.
New York: McGraw-Hill; 2008. p. 1746-62.
Risser A, Donovan D, Heintzman J, Page T. NSAID prescribing
precautions. Am Fam Physician. 2009;80(12):1371-8.
Tarigan P. Tukak gaster. In: Sudoyo AW, Simadibrata M, Setiyohadi
B, Setiati S, Alwi I, editors. Buku ajar ilmu penyakit dalam. 5th Ed.
Jakarta: Internal Publishing; 2009. p. 513-22.
Pisegna JR. Peptic ulcer disease. In: Bayless TM, Diehl AM,
editors. Advanced therapy in gastroenterology and liver disease.
5th Ed. London: B.C Decker Inc; 2005. p. 147-55.
Bertouch J, Stiel D. Non-steroidal anti-inflammatory drugs. In:
Yeomans N, editor. NSAIDs and the gastrointestinal track. 2nd
Ed. Sydney: Sydney NSW 2000; 2008. p. 6-17.
Blandizzi C, Tuccori M, Colucci R, Gori G, Fornai M, Antonioli
L, et al. Clinical efficacy of esomeprazole in the prevention and
healing of gastrointestinal toxicity associated with NSAIDs in
elderly patients. Drugs Aging. 2008;25:197-208.
Singh G, Triadafilopoulos G. Appropriate choice of proton pump
inhibitor therapy in the prevention and management of NSAIDrelated gastrointestinal damage. Int J Clin Pract. 2005;59:12107.
Scheiman JM, Cryer B. Panel discussion: treatment approaches
to control gastrointestinal risk and balance cardiovascular risks
and benefits: proposals and recommendations. Aliment Pharmacol
Ther Symp Ser. 2005;1:26-32.
Pelletier JM, Lajeunesse D, Reboul P, Pelletier JP. Therapeutic
role of dual inhibitors of 5-LOX and COX selective and nonselective non-steroidal anti-inflammatory drugs. Ann Rheum Dis.
2003;62:501-9.
14. Fendrick AM. COX-2 inhibitor use after vioxx: careful balance
of end of the rope? The Am J Manag Care. 2004;10:740-1.
15. Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR
and Gutthann SP. Risk of upper gastrointestinal complications
associated with cyclooxygenase-2 selective and nonselective
nonstreroidal anti-inflammatory drugs. Pharmacotherapy. 2009;
29(12):1397-407.
16. Lanza FL, Chan FKI, Quigley EMM. Guidelines for prevention
of NSAID-related ulcer complication. Am J Gastro. 2009;104:
728-38.
17. Elnacef N, Scheiman JM, Fendrick AM, Howden CW, Chey WD.
Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective
nonsteroidal anti-inflammatory drugs among US primary care
providers. Aliment Pharmacol Ther. 2008; 28(10):1249-58.
18. Papatheodoridis GV, Papadelli D, Cholongitas E, Vassilopoulos
D, Mentis A, Hadziyannis SJ. Effect of helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of
nonsteroid anti-inflammatory drugs. Am J Med. 2004;116:6015.
19. Sung JJY, Russel RI, Yeomans N, Chan FKL, Chen SL, Fock KM,
et al. Non-steroidal anti-inflammatory drug toxicity in the upper
gastrointestinal track. J Gastroenterol Hepatol. 2000;15:58-68.
20. Scheiman JM. Nonsteroidal anti-inflammatory drug (NSAID)induced gastropathy. In: Kim KE, editors. Acute gastrointestinal
bleeding. New Jersey: Humana Press; 2003. p. 75-96.
21. Pohle T, Brzozowski T, Becker JC, Vort IR, Markmann A,
Konturek SJ, et al. Role of reactive oxygen metabolites in aspirin-induced gastric damage in human: gastroprotection by vitamin C. Aliment Pharmacol Ther. 2001;15:677-87.
449